The Late-Stage Heart Failure Pipeline is Weak in Terms of Quantity and Quality, 81% of Products Are in Phase I and II Of Development.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland Ireland, Irish Eire (âr`ə) [to it are related the poetic Erin and perhaps the Latin Hibernia], island, 32,598 sq mi (84,429 sq km), second largest of the British Isles. -- Research and Markets (http://www.researchandmarkets.com/reports/c32787) has announced the addition of Chronic and Acute Heart Failure - Diversity and Disappointment to their offering. There is a clear need for new treatments for heart failure, as mortality and morbidity rates morbidity rate n. The proportion of patients with a particular disease during a given year per given unit of population. morbidity rate Epidemiology The number of cases of a particular disease in a unit of population , although improving, remain high. Heart failure already represents the leading cause of hospitalization hospitalization /hos·pi·tal·iza·tion/ (hos?pi-t'l-i-za´shun) 1. the placing of a patient in a hospital for treatment. 2. the term of confinement in a hospital. for patients over the age of 65 in Western markets and the aging population in these markets will surely lead to growth in the prevalence of the disease and an increase in healthcare expenditure. This report provides an assessment of the patient potential, including patient segmentation for developmental chronic and acute heart failure products. It gives an overview of the chronic and acute heart failure R&D pipeline with detailed information on the classes in development and provides commercial analysis, supported by the views of key opinion leaders, of key compounds in development in terms of their ability to satisfy unmet un·met adj. Not satisfied or fulfilled: unmet demands. needs. Sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for key late-stage developmental chronic and acute heart failure products in the seven major markets to 2014 are also provided. The late-stage heart failure pipeline is weak in terms of quantity and quality, 81% of products are in Phase I and II of development. The majority of pipeline products are being developed for chronic heart failure with only 33% being developed for acute heart failure. Developmental chronic heart failure products hold little commercial promise because they are primarily being developed as add-on A purchase of additional goods before payment is made for goods already purchased. An add-on may be covered by a clause in an installment payment contract that allows the seller to hold a security interest in the earlier goods until full payment is made on the later goods. therapies with niche-focused launch strategies and the increased use of devices in this area form strong competition. The acute heart failure pipeline has high commercial potential but safety issues have led to disappointment for levosimendan levosimendan Simdax® Cardiology A calcium-sensitizing agent which ↑ heart pump efficiency w/o ↑ O2 consumption or causing arrhythmias , leaving tolvaptan Tolvaptan (INN), also known as OPC-41061, is a selective, competitive arginine vasopressin receptor 2 antagonist under investigation as a potential treatment for fluid retention and hyponatremia (low blood sodium levels) associated with congestive heart failure. as the most promising acute heart failure product in the pipeline. Reasons to order your copy: - Gain insight into the current and future prospects for the chronic and acute heart failure market from key opinion leaders - Identify the opportunities and risks for late stage developmental products based on a structured assessment of clinical and commercial attractiveness - View independent sales forecasts for drugs in late-stage development for treatment of chronic and acute heart failure Topics covered in the report include: --Pipeline overview & future focus --Pipeline dynamics --R&d approach --Chronic heart failure late-stage drug analysis & forecasts --Comparative analysis of chronic heart failure pipeline --Acute heart failure late-stage drug analysis & forecasts --Comparative analysis of acute heart failure pipeline --Other chronic heart failure products --Other acute heart failure products --Innovative early-stage projects - acute and chronic For more information visit http://www.researchandmarkets.com/reports/c32787 Source: Datamonitor |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion